Merus N.V.

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, VRTX has a market cap of 101.9B. Regarding current trading prices, MRUS is priced at $66.95, while VRTX trades at $395.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas VRTX's P/E ratio is 28.25. In terms of profitability, MRUS's ROE is -0.55%, compared to VRTX's ROE of +0.22%. Regarding short-term risk, MRUS is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check VRTX's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, REGN has a market cap of 62.3B. Regarding current trading prices, MRUS is priced at $66.95, while REGN trades at $593.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas REGN's P/E ratio is 15.09. In terms of profitability, MRUS's ROE is -0.55%, compared to REGN's ROE of +0.15%. Regarding short-term risk, MRUS is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check REGN's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, ALNY has a market cap of 61.3B. Regarding current trading prices, MRUS is priced at $66.95, while ALNY trades at $458.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas ALNY's P/E ratio is -189.29. In terms of profitability, MRUS's ROE is -0.55%, compared to ALNY's ROE of -2.74%. Regarding short-term risk, MRUS is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check ALNY's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, MRUS is priced at $66.95, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas SGEN's P/E ratio is -57.19. In terms of profitability, MRUS's ROE is -0.55%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, MRUS is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check SGEN's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, ARGX has a market cap of 40.6B. Regarding current trading prices, MRUS is priced at $66.95, while ARGX trades at $663.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas ARGX's P/E ratio is 33.79. In terms of profitability, MRUS's ROE is -0.55%, compared to ARGX's ROE of +0.26%. Regarding short-term risk, MRUS is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check ARGX's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, BNTX has a market cap of 26.6B. Regarding current trading prices, MRUS is priced at $66.95, while BNTX trades at $111.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas BNTX's P/E ratio is -66.33. In terms of profitability, MRUS's ROE is -0.55%, compared to BNTX's ROE of -0.02%. Regarding short-term risk, MRUS is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check BNTX's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, MRUS is priced at $66.95, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas BGNE's P/E ratio is -22.55. In terms of profitability, MRUS's ROE is -0.55%, compared to BGNE's ROE of -0.05%. Regarding short-term risk, MRUS is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check BGNE's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, SMMT has a market cap of 19.3B. Regarding current trading prices, MRUS is priced at $66.95, while SMMT trades at $26.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas SMMT's P/E ratio is -25.75. In terms of profitability, MRUS's ROE is -0.55%, compared to SMMT's ROE of -2.09%. Regarding short-term risk, MRUS is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check SMMT's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, MRUS is priced at $66.95, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, MRUS's ROE is -0.55%, compared to DNA-WT's ROE of -0.45%. Regarding short-term risk, MRUS is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check DNA-WT's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, INCY has a market cap of 16.9B. Regarding current trading prices, MRUS is priced at $66.95, while INCY trades at $85.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas INCY's P/E ratio is 20.46. In terms of profitability, MRUS's ROE is -0.55%, compared to INCY's ROE of +0.24%. Regarding short-term risk, MRUS is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check INCY's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, RPRX has a market cap of 15.7B. Regarding current trading prices, MRUS is priced at $66.95, while RPRX trades at $36.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas RPRX's P/E ratio is 15.86. In terms of profitability, MRUS's ROE is -0.55%, compared to RPRX's ROE of +0.15%. Regarding short-term risk, MRUS is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check RPRX's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, GMAB has a market cap of 15.4B. Regarding current trading prices, MRUS is priced at $66.95, while GMAB trades at $24.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas GMAB's P/E ratio is 12.65. In terms of profitability, MRUS's ROE is -0.55%, compared to GMAB's ROE of +0.28%. Regarding short-term risk, MRUS is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check GMAB's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, UTHR has a market cap of 14.1B. Regarding current trading prices, MRUS is priced at $66.95, while UTHR trades at $314.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas UTHR's P/E ratio is 12.13. In terms of profitability, MRUS's ROE is -0.55%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, MRUS is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check UTHR's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, MRUS is priced at $66.95, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas KRTX's P/E ratio is -28.09. In terms of profitability, MRUS's ROE is -0.55%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, MRUS is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check KRTX's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, ASND has a market cap of 11.7B. Regarding current trading prices, MRUS is priced at $66.95, while ASND trades at $194.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas ASND's P/E ratio is -36.52. In terms of profitability, MRUS's ROE is -0.55%, compared to ASND's ROE of +1.52%. Regarding short-term risk, MRUS is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check ASND's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, BMRN has a market cap of 11.2B. Regarding current trading prices, MRUS is priced at $66.95, while BMRN trades at $58.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas BMRN's P/E ratio is 17.13. In terms of profitability, MRUS's ROE is -0.55%, compared to BMRN's ROE of +0.11%. Regarding short-term risk, MRUS is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check BMRN's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, EXEL has a market cap of 10.4B. Regarding current trading prices, MRUS is priced at $66.95, while EXEL trades at $38.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas EXEL's P/E ratio is 18.61. In terms of profitability, MRUS's ROE is -0.55%, compared to EXEL's ROE of +0.28%. Regarding short-term risk, MRUS is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check EXEL's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, MRNA has a market cap of 10.2B. Regarding current trading prices, MRUS is priced at $66.95, while MRNA trades at $27.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas MRNA's P/E ratio is -3.49. In terms of profitability, MRUS's ROE is -0.55%, compared to MRNA's ROE of -0.27%. Regarding short-term risk, MRUS is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check MRNA's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, BBIO has a market cap of 9.6B. Regarding current trading prices, MRUS is priced at $66.95, while BBIO trades at $49.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas BBIO's P/E ratio is -12.16. In terms of profitability, MRUS's ROE is -0.55%, compared to BBIO's ROE of +0.51%. Regarding short-term risk, MRUS is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check BBIO's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, MRUS is priced at $66.95, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas RXDX's P/E ratio is -56.47. In terms of profitability, MRUS's ROE is -0.55%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, MRUS is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check RXDX's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, MDGL has a market cap of 9.1B. Regarding current trading prices, MRUS is priced at $66.95, while MDGL trades at $410.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas MDGL's P/E ratio is -32.21. In terms of profitability, MRUS's ROE is -0.55%, compared to MDGL's ROE of -0.38%. Regarding short-term risk, MRUS is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check MDGL's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, VRNA has a market cap of 9B. Regarding current trading prices, MRUS is priced at $66.95, while VRNA trades at $105.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas VRNA's P/E ratio is -100.43. In terms of profitability, MRUS's ROE is -0.55%, compared to VRNA's ROE of -0.39%. Regarding short-term risk, MRUS is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check VRNA's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, MRUS is priced at $66.95, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas IMGN's P/E ratio is -111.55. In terms of profitability, MRUS's ROE is -0.55%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, MRUS is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check IMGN's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, TECH has a market cap of 8.5B. Regarding current trading prices, MRUS is priced at $66.95, while TECH trades at $56.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas TECH's P/E ratio is 117.39. In terms of profitability, MRUS's ROE is -0.55%, compared to TECH's ROE of +0.06%. Regarding short-term risk, MRUS is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check TECH's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, HALO has a market cap of 8.4B. Regarding current trading prices, MRUS is priced at $66.95, while HALO trades at $71.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas HALO's P/E ratio is 16.39. In terms of profitability, MRUS's ROE is -0.55%, compared to HALO's ROE of +1.37%. Regarding short-term risk, MRUS is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check HALO's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, MRUS is priced at $66.95, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas BPMC's P/E ratio is -51.58. In terms of profitability, MRUS's ROE is -0.55%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, MRUS is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check BPMC's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, MRUS is priced at $66.95, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas CERE's P/E ratio is -16.47. In terms of profitability, MRUS's ROE is -0.55%, compared to CERE's ROE of -0.72%. Regarding short-term risk, MRUS is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check CERE's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, ROIV has a market cap of 8.1B. Regarding current trading prices, MRUS is priced at $66.95, while ROIV trades at $11.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas ROIV's P/E ratio is -10.83. In terms of profitability, MRUS's ROE is -0.55%, compared to ROIV's ROE of -0.10%. Regarding short-term risk, MRUS is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check ROIV's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, MRUS is priced at $66.95, while ROIVW trades at $2.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, MRUS's ROE is -0.55%, compared to ROIVW's ROE of -0.10%. Regarding short-term risk, MRUS is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check ROIVW's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, CORT has a market cap of 7.5B. Regarding current trading prices, MRUS is priced at $66.95, while CORT trades at $70.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas CORT's P/E ratio is 63.38. In terms of profitability, MRUS's ROE is -0.55%, compared to CORT's ROE of +0.20%. Regarding short-term risk, MRUS is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check CORT's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, JAZZ has a market cap of 7.3B. Regarding current trading prices, MRUS is priced at $66.95, while JAZZ trades at $123.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas JAZZ's P/E ratio is -17.24. In terms of profitability, MRUS's ROE is -0.55%, compared to JAZZ's ROE of -0.10%. Regarding short-term risk, MRUS is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check JAZZ's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, IONS has a market cap of 6.9B. Regarding current trading prices, MRUS is priced at $66.95, while IONS trades at $42.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas IONS's P/E ratio is -24.57. In terms of profitability, MRUS's ROE is -0.55%, compared to IONS's ROE of -0.45%. Regarding short-term risk, MRUS is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check IONS's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, RVMD has a market cap of 6.8B. Regarding current trading prices, MRUS is priced at $66.95, while RVMD trades at $37.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas RVMD's P/E ratio is -8.07. In terms of profitability, MRUS's ROE is -0.55%, compared to RVMD's ROE of -0.42%. Regarding short-term risk, MRUS is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check RVMD's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, MRUS is priced at $66.95, while RYTM trades at $104.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas RYTM's P/E ratio is -33.78. In terms of profitability, MRUS's ROE is -0.55%, compared to RYTM's ROE of -1.55%. Regarding short-term risk, MRUS is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check RYTM's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, MRUS is priced at $66.95, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas RETA's P/E ratio is -66.29. In terms of profitability, MRUS's ROE is -0.55%, compared to RETA's ROE of +0.47%. Regarding short-term risk, MRUS is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check RETA's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, AXSM has a market cap of 5.8B. Regarding current trading prices, MRUS is priced at $66.95, while AXSM trades at $119.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas AXSM's P/E ratio is -23.15. In terms of profitability, MRUS's ROE is -0.55%, compared to AXSM's ROE of -3.58%. Regarding short-term risk, MRUS is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check AXSM's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, RNA has a market cap of 5.7B. Regarding current trading prices, MRUS is priced at $66.95, while RNA trades at $46.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas RNA's P/E ratio is -12.54. In terms of profitability, MRUS's ROE is -0.55%, compared to RNA's ROE of -0.33%. Regarding short-term risk, MRUS is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check RNA's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, ABVX has a market cap of 5.6B. Regarding current trading prices, MRUS is priced at $66.95, while ABVX trades at $77.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas ABVX's P/E ratio is -21.64. In terms of profitability, MRUS's ROE is -0.55%, compared to ABVX's ROE of -1.62%. Regarding short-term risk, MRUS is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check ABVX's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, MRUS is priced at $66.95, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, MRUS's ROE is -0.55%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, MRUS is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check ABCM's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, MRUS is priced at $66.95, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas ISEE's P/E ratio is -22.44. In terms of profitability, MRUS's ROE is -0.55%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, MRUS is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check ISEE's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, NUVL has a market cap of 5.3B. Regarding current trading prices, MRUS is priced at $66.95, while NUVL trades at $76.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas NUVL's P/E ratio is -14.97. In terms of profitability, MRUS's ROE is -0.55%, compared to NUVL's ROE of -0.33%. Regarding short-term risk, MRUS is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check NUVL's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, CRSP has a market cap of 4.8B. Regarding current trading prices, MRUS is priced at $66.95, while CRSP trades at $54.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas CRSP's P/E ratio is -9.78. In terms of profitability, MRUS's ROE is -0.55%, compared to CRSP's ROE of -0.25%. Regarding short-term risk, MRUS is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check CRSP's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, ALKS has a market cap of 4.8B. Regarding current trading prices, MRUS is priced at $66.95, while ALKS trades at $29.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas ALKS's P/E ratio is 14.04. In terms of profitability, MRUS's ROE is -0.55%, compared to ALKS's ROE of +0.24%. Regarding short-term risk, MRUS is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check ALKS's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, TGTX has a market cap of 4.6B. Regarding current trading prices, MRUS is priced at $66.95, while TGTX trades at $29.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas TGTX's P/E ratio is 75.71. In terms of profitability, MRUS's ROE is -0.55%, compared to TGTX's ROE of +0.29%. Regarding short-term risk, MRUS is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check TGTX's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, CYTK has a market cap of 4.6B. Regarding current trading prices, MRUS is priced at $66.95, while CYTK trades at $38.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas CYTK's P/E ratio is -7.43. In terms of profitability, MRUS's ROE is -0.55%, compared to CYTK's ROE of +3.09%. Regarding short-term risk, MRUS is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check CYTK's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, AAPG has a market cap of 4.6B. Regarding current trading prices, MRUS is priced at $66.95, while AAPG trades at $47.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas AAPG's P/E ratio is -65.53. In terms of profitability, MRUS's ROE is -0.55%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, MRUS is less volatile compared to AAPG. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check AAPG's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, MRUS is priced at $66.95, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas ALPN's P/E ratio is -101.52. In terms of profitability, MRUS's ROE is -0.55%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, MRUS is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check ALPN's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, KRYS has a market cap of 4.2B. Regarding current trading prices, MRUS is priced at $66.95, while KRYS trades at $149.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas KRYS's P/E ratio is 29.61. In terms of profitability, MRUS's ROE is -0.55%, compared to KRYS's ROE of +0.15%. Regarding short-term risk, MRUS is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check KRYS's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, MRUS is priced at $66.95, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas OPT's P/E ratio is -1.52. In terms of profitability, MRUS's ROE is -0.55%, compared to OPT's ROE of +2.60%. Regarding short-term risk, MRUS is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check OPT's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, ACAD has a market cap of 4.2B. Regarding current trading prices, MRUS is priced at $66.95, while ACAD trades at $25.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas ACAD's P/E ratio is 18.64. In terms of profitability, MRUS's ROE is -0.55%, compared to ACAD's ROE of +0.31%. Regarding short-term risk, MRUS is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check ACAD's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, PCVX has a market cap of 4.1B. Regarding current trading prices, MRUS is priced at $66.95, while PCVX trades at $32.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas PCVX's P/E ratio is -7.76. In terms of profitability, MRUS's ROE is -0.55%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, MRUS is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check PCVX's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, MRUS is priced at $66.95, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas MRTX's P/E ratio is -4.82. In terms of profitability, MRUS's ROE is -0.55%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, MRUS is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check MRTX's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, TLX has a market cap of 4.1B. Regarding current trading prices, MRUS is priced at $66.95, while TLX trades at $12.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas TLX's P/E ratio is 134.33. In terms of profitability, MRUS's ROE is -0.55%, compared to TLX's ROE of +0.10%. Regarding short-term risk, MRUS is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check TLX's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, ADMA has a market cap of 4.1B. Regarding current trading prices, MRUS is priced at $66.95, while ADMA trades at $17.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas ADMA's P/E ratio is 20.12. In terms of profitability, MRUS's ROE is -0.55%, compared to ADMA's ROE of +0.62%. Regarding short-term risk, MRUS is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check ADMA's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, ACLX has a market cap of 4B. Regarding current trading prices, MRUS is priced at $66.95, while ACLX trades at $71.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas ACLX's P/E ratio is -21.05. In terms of profitability, MRUS's ROE is -0.55%, compared to ACLX's ROE of -0.43%. Regarding short-term risk, MRUS is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check ACLX's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, PTCT has a market cap of 3.9B. Regarding current trading prices, MRUS is priced at $66.95, while PTCT trades at $50.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas PTCT's P/E ratio is 6.94. In terms of profitability, MRUS's ROE is -0.55%, compared to PTCT's ROE of -0.99%. Regarding short-term risk, MRUS is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check PTCT's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, AKRO has a market cap of 3.9B. Regarding current trading prices, MRUS is priced at $66.95, while AKRO trades at $48.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas AKRO's P/E ratio is -12.67. In terms of profitability, MRUS's ROE is -0.55%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, MRUS is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check AKRO's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, MRUS is priced at $66.95, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas RYZB's P/E ratio is -57.86. In terms of profitability, MRUS's ROE is -0.55%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, MRUS is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check RYZB's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, ZLAB has a market cap of 3.7B. Regarding current trading prices, MRUS is priced at $66.95, while ZLAB trades at $35.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas ZLAB's P/E ratio is -16.99. In terms of profitability, MRUS's ROE is -0.55%, compared to ZLAB's ROE of -0.27%. Regarding short-term risk, MRUS is less volatile compared to ZLAB. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check ZLAB's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, MRUS is priced at $66.95, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas CBAY's P/E ratio is -32.81. In terms of profitability, MRUS's ROE is -0.55%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, MRUS is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check CBAY's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, SLNO has a market cap of 3.7B. Regarding current trading prices, MRUS is priced at $66.95, while SLNO trades at $69.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas SLNO's P/E ratio is -16.54. In terms of profitability, MRUS's ROE is -0.55%, compared to SLNO's ROE of -0.74%. Regarding short-term risk, MRUS is less volatile compared to SLNO. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check SLNO's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, MRUS is priced at $66.95, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas SWTX's P/E ratio is -13.78. In terms of profitability, MRUS's ROE is -0.55%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, MRUS is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check SWTX's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, APLS has a market cap of 3.5B. Regarding current trading prices, MRUS is priced at $66.95, while APLS trades at $27.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas APLS's P/E ratio is -15.09. In terms of profitability, MRUS's ROE is -0.55%, compared to APLS's ROE of -1.16%. Regarding short-term risk, MRUS is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check APLS's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, PTGX has a market cap of 3.5B. Regarding current trading prices, MRUS is priced at $66.95, while PTGX trades at $57.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas PTGX's P/E ratio is 76.77. In terms of profitability, MRUS's ROE is -0.55%, compared to PTGX's ROE of +0.08%. Regarding short-term risk, MRUS is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check PTGX's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, MIRM has a market cap of 3.5B. Regarding current trading prices, MRUS is priced at $66.95, while MIRM trades at $71.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas MIRM's P/E ratio is -57.07. In terms of profitability, MRUS's ROE is -0.55%, compared to MIRM's ROE of -0.25%. Regarding short-term risk, MRUS is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check MIRM's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, MTSR has a market cap of 3.4B. Regarding current trading prices, MRUS is priced at $66.95, while MTSR trades at $34.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas MTSR's P/E ratio is -11.16. In terms of profitability, MRUS's ROE is -0.55%, compared to MTSR's ROE of -0.90%. Regarding short-term risk, MRUS is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check MTSR's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, MLTX has a market cap of 3.4B. Regarding current trading prices, MRUS is priced at $66.95, while MLTX trades at $55.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas MLTX's P/E ratio is -19.42. In terms of profitability, MRUS's ROE is -0.55%, compared to MLTX's ROE of -0.42%. Regarding short-term risk, MRUS is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check MLTX's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, SRRK has a market cap of 3.3B. Regarding current trading prices, MRUS is priced at $66.95, while SRRK trades at $35.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas SRRK's P/E ratio is -11.85. In terms of profitability, MRUS's ROE is -0.55%, compared to SRRK's ROE of -1.27%. Regarding short-term risk, MRUS is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check SRRK's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, LEGN has a market cap of 3.3B. Regarding current trading prices, MRUS is priced at $66.95, while LEGN trades at $35.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas LEGN's P/E ratio is -19.96. In terms of profitability, MRUS's ROE is -0.55%, compared to LEGN's ROE of -0.31%. Regarding short-term risk, MRUS is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check LEGN's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, LGND has a market cap of 3.1B. Regarding current trading prices, MRUS is priced at $66.95, while LGND trades at $158.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas LGND's P/E ratio is -38.94. In terms of profitability, MRUS's ROE is -0.55%, compared to LGND's ROE of -0.09%. Regarding short-term risk, MRUS is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check LGND's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, KYMR has a market cap of 3B. Regarding current trading prices, MRUS is priced at $66.95, while KYMR trades at $44.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas KYMR's P/E ratio is -12.20. In terms of profitability, MRUS's ROE is -0.55%, compared to KYMR's ROE of -0.32%. Regarding short-term risk, MRUS is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check KYMR's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, XENE has a market cap of 2.9B. Regarding current trading prices, MRUS is priced at $66.95, while XENE trades at $38.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas XENE's P/E ratio is -10.75. In terms of profitability, MRUS's ROE is -0.55%, compared to XENE's ROE of -0.39%. Regarding short-term risk, MRUS is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check XENE's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, VKTX has a market cap of 2.9B. Regarding current trading prices, MRUS is priced at $66.95, while VKTX trades at $26.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas VKTX's P/E ratio is -16.66. In terms of profitability, MRUS's ROE is -0.55%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, MRUS is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check VKTX's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, ARWR has a market cap of 2.9B. Regarding current trading prices, MRUS is priced at $66.95, while ARWR trades at $21.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas ARWR's P/E ratio is -17.29. In terms of profitability, MRUS's ROE is -0.55%, compared to ARWR's ROE of -0.41%. Regarding short-term risk, MRUS is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check ARWR's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, MRUS is priced at $66.95, while MORF trades at $56.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas MORF's P/E ratio is -14.88. In terms of profitability, MRUS's ROE is -0.55%, compared to MORF's ROE of -0.16%. Regarding short-term risk, MRUS is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check MORF's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, MRUS is priced at $66.95, while MOR trades at $18.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas MOR's P/E ratio is -12.64. In terms of profitability, MRUS's ROE is -0.55%, compared to MOR's ROE of -1.84%. Regarding short-term risk, MRUS is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check MOR's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, RARE has a market cap of 2.8B. Regarding current trading prices, MRUS is priced at $66.95, while RARE trades at $29.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas RARE's P/E ratio is -5.39. In terms of profitability, MRUS's ROE is -0.55%, compared to RARE's ROE of -2.37%. Regarding short-term risk, MRUS is less volatile compared to RARE. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check RARE's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, CRNX has a market cap of 2.8B. Regarding current trading prices, MRUS is priced at $66.95, while CRNX trades at $30.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas CRNX's P/E ratio is -7.17. In terms of profitability, MRUS's ROE is -0.55%, compared to CRNX's ROE of -0.32%. Regarding short-term risk, MRUS is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check CRNX's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, NAMS has a market cap of 2.8B. Regarding current trading prices, MRUS is priced at $66.95, while NAMS trades at $25.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas NAMS's P/E ratio is -15.37. In terms of profitability, MRUS's ROE is -0.55%, compared to NAMS's ROE of -0.25%. Regarding short-term risk, MRUS is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check NAMS's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, MRUS is priced at $66.95, while KDNY trades at $40.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas KDNY's P/E ratio is -12.47. In terms of profitability, MRUS's ROE is -0.55%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, MRUS is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check KDNY's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, MRUS is priced at $66.95, while MYOV trades at $26.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas MYOV's P/E ratio is -14.05. In terms of profitability, MRUS's ROE is -0.55%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, MRUS is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check MYOV's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, IMVT has a market cap of 2.6B. Regarding current trading prices, MRUS is priced at $66.95, while IMVT trades at $15.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas IMVT's P/E ratio is -5.23. In terms of profitability, MRUS's ROE is -0.55%, compared to IMVT's ROE of -0.84%. Regarding short-term risk, MRUS is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check IMVT's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, CPRX has a market cap of 2.5B. Regarding current trading prices, MRUS is priced at $66.95, while CPRX trades at $20.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas CPRX's P/E ratio is 12.46. In terms of profitability, MRUS's ROE is -0.55%, compared to CPRX's ROE of +0.27%. Regarding short-term risk, MRUS is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check CPRX's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, KNSA has a market cap of 2.5B. Regarding current trading prices, MRUS is priced at $66.95, while KNSA trades at $33.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas KNSA's P/E ratio is 671.60. In terms of profitability, MRUS's ROE is -0.55%, compared to KNSA's ROE of +0.01%. Regarding short-term risk, MRUS is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check KNSA's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, TARS has a market cap of 2.4B. Regarding current trading prices, MRUS is priced at $66.95, while TARS trades at $57.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas TARS's P/E ratio is -24.69. In terms of profitability, MRUS's ROE is -0.55%, compared to TARS's ROE of -0.32%. Regarding short-term risk, MRUS is less volatile compared to TARS. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check TARS's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, MRUS is priced at $66.95, while PRVB trades at $24.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas PRVB's P/E ratio is -16.43. In terms of profitability, MRUS's ROE is -0.55%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, MRUS is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check PRVB's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, LQDA has a market cap of 2.4B. Regarding current trading prices, MRUS is priced at $66.95, while LQDA trades at $27.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas LQDA's P/E ratio is -15.00. In terms of profitability, MRUS's ROE is -0.55%, compared to LQDA's ROE of -1.58%. Regarding short-term risk, MRUS is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check LQDA's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, CNTA has a market cap of 2.3B. Regarding current trading prices, MRUS is priced at $66.95, while CNTA trades at $17.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas CNTA's P/E ratio is -9.48. In terms of profitability, MRUS's ROE is -0.55%, compared to CNTA's ROE of -0.56%. Regarding short-term risk, MRUS is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check CNTA's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, FOLD has a market cap of 2.3B. Regarding current trading prices, MRUS is priced at $66.95, while FOLD trades at $7.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas FOLD's P/E ratio is -63.33. In terms of profitability, MRUS's ROE is -0.55%, compared to FOLD's ROE of -0.20%. Regarding short-term risk, MRUS is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check FOLD's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, MRUS is priced at $66.95, while LBPH trades at $59.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas LBPH's P/E ratio is -26.66. In terms of profitability, MRUS's ROE is -0.55%, compared to LBPH's ROE of -0.21%. Regarding short-term risk, MRUS is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check LBPH's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, VCYT has a market cap of 2.3B. Regarding current trading prices, MRUS is priced at $66.95, while VCYT trades at $31.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas VCYT's P/E ratio is 86.56. In terms of profitability, MRUS's ROE is -0.55%, compared to VCYT's ROE of +0.02%. Regarding short-term risk, MRUS is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check VCYT's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, MRUS is priced at $66.95, while DICE trades at $47.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas DICE's P/E ratio is -21.91. In terms of profitability, MRUS's ROE is -0.55%, compared to DICE's ROE of +0.56%. Regarding short-term risk, MRUS is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check DICE's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, DNLI has a market cap of 2.2B. Regarding current trading prices, MRUS is priced at $66.95, while DNLI trades at $15.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas DNLI's P/E ratio is -5.42. In terms of profitability, MRUS's ROE is -0.55%, compared to DNLI's ROE of -0.41%. Regarding short-term risk, MRUS is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check DNLI's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, AGIO has a market cap of 2.2B. Regarding current trading prices, MRUS is priced at $66.95, while AGIO trades at $39.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas AGIO's P/E ratio is 3.38. In terms of profitability, MRUS's ROE is -0.55%, compared to AGIO's ROE of +0.43%. Regarding short-term risk, MRUS is less volatile compared to AGIO. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check AGIO's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, APGE has a market cap of 2.2B. Regarding current trading prices, MRUS is priced at $66.95, while APGE trades at $38.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas APGE's P/E ratio is -8.78. In terms of profitability, MRUS's ROE is -0.55%, compared to APGE's ROE of -0.23%. Regarding short-term risk, MRUS is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check APGE's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, IDYA has a market cap of 2.2B. Regarding current trading prices, MRUS is priced at $66.95, while IDYA trades at $25.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas IDYA's P/E ratio is -6.41. In terms of profitability, MRUS's ROE is -0.55%, compared to IDYA's ROE of -0.31%. Regarding short-term risk, MRUS is less volatile compared to IDYA. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check IDYA's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, MRUS is priced at $66.95, while CALT trades at $40.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas CALT's P/E ratio is -22.73. In terms of profitability, MRUS's ROE is -0.55%, compared to CALT's ROE of -1.67%. Regarding short-term risk, MRUS is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check CALT's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, HRMY has a market cap of 2.1B. Regarding current trading prices, MRUS is priced at $66.95, while HRMY trades at $37.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas HRMY's P/E ratio is 12.03. In terms of profitability, MRUS's ROE is -0.55%, compared to HRMY's ROE of +0.26%. Regarding short-term risk, MRUS is more volatile compared to HRMY. This indicates potentially higher risk in terms of short-term price fluctuations for MRUS.Check HRMY's competition here

MRUS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRUS stands at 5B. In comparison, CELC has a market cap of 2.1B. Regarding current trading prices, MRUS is priced at $66.95, while CELC trades at $51.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRUS currently has a P/E ratio of -11.94, whereas CELC's P/E ratio is -14.52. In terms of profitability, MRUS's ROE is -0.55%, compared to CELC's ROE of -1.50%. Regarding short-term risk, MRUS is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for MRUS.Check CELC's competition here